financetom
Business
financetom
/
Business
/
Snowline Gold Raising $20-Million in a Bought-Deal Private Placement of Flow-Through Shares
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Snowline Gold Raising $20-Million in a Bought-Deal Private Placement of Flow-Through Shares
Mar 17, 2025 9:38 AM

12:17 PM EDT, 03/17/2025 (MT Newswires) -- Snowline Gold ( SNWGF ) Monday said it is raising $20.02 million in a bought-deal private placement of flow-through shares.

The company said it is selling underwriters 1.87 million flow-through shares at a price of $10.68 per Charity FT share.

"This financing will serve to top up an already strong treasury for Snowline, allowing for efficient use of exploration capital and providing a long runway to continue our exploration this year and next as we work to unlock a district," said chief executive Scott Berdahl. "At the same time, it will free up existing capital for the rapid, efficient advancement of important work on the Valley deposit, including engineering and environmental studies. We are excited to ramp up our efforts on multiple fronts as we head into the 2025 field season."

Snowline shares were last seen down $0.13 to $8.05 on the TSX Venture Exchange.

Price: 8.09, Change: -0.08, Percent Change: -1.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mobility tech firm ECARX turns profitable on higher shipment volumes in Q3 
Mobility tech firm ECARX turns profitable on higher shipment volumes in Q3 
Nov 3, 2025
Overview * ECARX ( ECX ) Q3 revenue grows 11% YoY to $219.9 mln, driven by higher shipment volumes * Company achieves first net profit of $0.9 mln, compared to a loss last year * Adjusted EBITDA reaches $8.3 mln, reflecting improved operational efficiency Outlook * ECARX ( ECX ) expects to maintain growth momentum into next quarter and beyond...
Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand
Scientific instruments maker Bruker beats Q3 estimates, cuts FY guidance on weak demand
Nov 3, 2025
Overview * Bruker Q3 2025 revenue of $860.5 mln beats analyst expectations despite a 0.5% yoy decline * Adjusted EPS for Q3 2025 beats consensus at $0.45, despite a decline from last year * Company lowers FY2025 guidance, citing weaker demand and EPS dilution from higher share count Outlook * Bruker ( BRKR ) expects FY2025 revenue of $3.41 to...
TG Therapeutics Q3 revenue up on strong demand, raises 2025 forecast
TG Therapeutics Q3 revenue up on strong demand, raises 2025 forecast
Nov 3, 2025
Overview * TG Therapeutics Q3 2025 revenue was $161.7 mln, driven by BRIUMVI sales * Company raises 2025 global revenue target to $600 mln, BRIUMVI U.S. target to $585 mln * Completed $100 mln share repurchase, authorized additional $100 mln program Outlook * TG Therapeutics ( TGTX ) raises 2025 global revenue target to $600 mln * Company increases 2025...
Karyopharm Therapeutics' Q3 net loss widens
Karyopharm Therapeutics' Q3 net loss widens
Nov 3, 2025
Overview * Karyopharm Q3 total revenue rises to $44 mln, driven by XPOVIO sales growth * Net loss for Q3 2025 was $33.1 mln, slightly higher than last year * Company reaffirms full-year 2025 revenue guidance of $140 mln to $155 mln Outlook * Karyopharm reaffirms 2025 total revenue guidance of $140 mln to $155 mln * Company expects 2025...
Copyright 2023-2026 - www.financetom.com All Rights Reserved